Search

Your search keyword '"Alain Luciani"' showing total 188 results

Search Constraints

Start Over You searched for: Author "Alain Luciani" Remove constraint Author: "Alain Luciani" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
188 results on '"Alain Luciani"'

Search Results

1. Evaluation of a new beads reflux control microcatheter in drug-eluting bead transarterial chemoembolization

2. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma

Catalog

Books, media, physical & digital resources

3. Combination of intrahepatic TARE and extrahepatic TACE to treat HCC patients with extrahepatic artery supply: A case series

4. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?

5. Automated CT LI-RADS v2018 scoring of liver observations using machine learning: A multivendor, multicentre retrospective study

6. TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial

7. Myosteatosis as an independent risk factor for mortality after kidney allograft transplantation: a retrospective cohort study

8. Liver resection for single large hepatocellular carcinoma: a prognostic factors study

9. 2020 WSES guidelines for the detection and management of bile duct injury during cholecystectomy

10. Predictors of mortality following emergency open colectomy for ischemic colitis: a single-center experience

11. Abdominal imaging in ICU patients with viral pneumonia: Are findings in COVID-19 patients really different from those observed with non-SARS-CoV-2 viral pneumonia?

12. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area

13. Correction: Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis.

14. Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis.

15. Multiple gas emboli complicating an emphysematous pyelonephritis

16. Metabolic Tumour Burden Measured by 18F-FDG PET/CT Predicts Malignant Transformation in Patients with Neurofibromatosis Type-1.

18. Accuracy and reproducibility of a cone beam CT-based virtual parenchymal perfusion algorithm in the prediction of SPECT/CT anatomical and volumetric results during the planification of radioembolization for HCC

19. MRI features associated with HCC histologic subtypes: a western American and European bicenter study

20. Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge

22. Synthetic MR image generation of macrotrabecular-massive hepatocellular carcinoma using generative adversarial networks

23. Fat in mass in primary liver lesions: are usual MRI diagnostic criteria of both malignant and benign liver lesions still applicable?

24. Myosteatosis as an independent risk factor for mortality after kidney allograft transplantation: a retrospective cohort study

25. Utility of Early Posttreatment PET/CT Evaluation Using FDG or 18F-FCH to Predict Response to 90Y Radioembolization in Patients With Hepatocellular Carcinoma

26. Interleukin-17 programs liver progenitor cell transformation into cancer stem cells through mir-122 downregulation with increased risk of primary liver cancer initiation

27. Supplementary Table 8 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

28. Supplementary Table 7 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

29. Supplementary Data from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

30. Supplementary Table 5 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

31. Supplementary Table 3 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

32. Supplementary Data from ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma

33. Supplementary Table 1 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

34. Supplementary Table 6 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

35. Supplementary Table 4 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

36. Data from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy

37. Data from ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma

38. Development and validation of a new equation based on plasma creatinine and muscle mass assessed by CT scan to estimate glomerular filtration rate: a cross-sectional study

39. Recommandation opérationnelle en radiologie interventionnelle : chimioembolisation hépatique

40. Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma

41. Chest <scp>PET</scp> / <scp>MRI</scp> in Solid Cancers: Comparing the Diagnostic Performance of a Free‐Breathing <scp>3D‐T1‐GRE</scp> Stack‐of‐Stars Volume Interpolated Breath‐Hold Examination ( <scp>StarVIBE</scp> ) Acquisition With That of a <scp>3D‐T1‐GRE</scp> Volume Interpolated Breath‐Hold Examination ( <scp>VIBE</scp> ) for Chest Staging During Whole‐Body <scp>PET</scp> / <scp>MRI</scp>

43. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)

44. Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort

45. Focal Benign Liver Lesions and Their Diagnostic Pitfalls

46. Tumeur Triton maligne : à propos d’un cas

47. Intentional R1 resection of liver metastases: A new treatment paradigm for patients with advanced colorectal cancer based on a propensity score–Matched case-control analysis

48. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial

49. Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

50. Fast T2-weighted liver MRI: Image quality and solid focal lesions conspicuity using a deep learning accelerated single breath-hold HASTE fat-suppressed sequence